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Abstract
Acromegaly results from oversecretion of growth hormone and subsequent 
insulin growth factor-I. Some studies have described an association between 
acromegaly and increased risk of some cancers, including thyroid cancer, the most 
common endocrine malignancy. It is well known that follicular thyroid cells express 
IGF-I receptor and that GH and IGF-I have both proliferative and anti-apoptotic 
effects and their hypersecretion may theoretically induce tumor development 
and stimulate its growth, despite the fact that research data is conflicting and 
population-based data on thyroid cancer and acromegaly is rare. Some molecular 
alterations, including point mutations in BRAF and RAS genes and RET/PTC gene 
rearrangements, have been associated with oncogenesis of PTC. However, the 
implications of these genetic markers in the development of PTC in patients with 
acromegaly are not yet well known. In this chapter, we discuss epidemiology, patho-
genesis, molecular biology aspects, and how to screen and to manage acromegalic 
patients with nodular thyroid disease and thyroid cancer.
Keywords: acromegaly and thyroid cancer, IGF-I and cancer, thyroid and 
acromegaly, GH and cancer, molecular markers and thyroid cancer
1. Introduction
Acromegaly is a rare disease that results from the oversecretion of growth hor-
mone (GH) and subsequent insulin growth factor I (IGF-I) [1]. It is associated with 
important complications that may reduce life expectancy of these patients [2, 3].
Most acromegalic patients die from cardiovascular, cerebrovascular, or respira-
tory diseases [3, 4]. Nevertheless, in the past two decades, some studies have also 
described an association between acromegaly and an increased risk of some cancers 
such as colorectal and thyroid cancer (TC), which is the most common endocrine 
malignancy, among others [5].
Part of the difficulty in determining the true incidence of cancer in this popula-
tion is due to the relative rarity of acromegaly [6]. On the other hand, with improve-
ment in surgical and radiotherapeutic procedures as well as advances in medical 
treatment, an increase of the survival rate of patients with acromegaly has been 
shown. As a result, patients may have a longer exposure to high GH levels [7].
As the prevalence of thyroid cancer has been shown to increase among patients 
with acromegaly, this should draw attention for clinicians to investigate thyroid 
disease, particularly thyroid cancer.
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2. Epidemiology
The association between acromegaly and TC is supported by preclinical data 
showing that GH-IGF system plays an important role in cancer development and 
progression [6]. However, clinical studies that addressed the association between 
acromegaly and cancer produced controversial results, partly due to the different 
methodological approaches used (case-control and population-based designs) [8].
A comprehensive meta-analysis showed an increased risk of both nodular thy-
roid disease (NTD) (OR = 6.9, RR = 2.1) and TC (OR = 7.5, RR = 7.2) in acromegaly. 
It showed a prevalence slightly below 60% of NTD and of around 4% of TC [8]. 
Within this context, a consistent Brazilian multicentric study with 124 acromegalic 
patients in a case-control design showed a higher prevalence of 7.2% for TC and 
0.7% in the control group [9].
These findings may result from the fact of improving diagnostic and treatment 
of acromegaly extending the life duration which increases the prevalence of both 
benign and malignant neoplasms [3–11].
On the other hand, the co-occurrence of autoimmune thyroid diseases and acro-
megaly is not common. So far only a handful of cases of Graves-Basedow disease 
in acromegalic patients have been reported, while Hashimoto’s disease occurs more 
frequently (4.6%) [12, 13].
3. Molecular pathogenesis of TC in acromegalic patients
3.1 Molecular basis of acromegaly
The pituitary gland integrates hormonal signs that control several homeostatic 
processes such as metabolism, growth, and reproduction. Cell clusters localized 
in the anterior pituitary, somatotrophs, secrete GH responsible for cellular pro-
liferation through membrane-bound growth hormone receptor (GHR) present in 
various organs and systems [14]. The interaction between GH and GHR results in 
activation of intracellular protein Janus kinase 2 (JAK2). As shown in Figure 1, once 
phosphorylated JAK2 activates the signal transducers and activators of transcrip-
tion (STAT) protein that is translocated to the nucleus and initiates transcription of 
genes in response to GH [15], the STAT is able to bind to IGF-I promoter regulating 
the transcription of this gene [16]. Thus, the presence of GH can induce the synthe-
sis of IGF-I that occurs mainly in the liver and is composed of 70 amino acids and 
has mitotic and anti-apoptotic effects [1].
In the vast majority of cases, the excess of GH in acromegaly is originated from 
proliferating somatotrophs (somatotropinoma). The pituitary adenomas are of 
monoclonal origin, indicating that the tumor rises from a single cell that acquires 
proliferative advantage [17]. The primary defect that leads to development of 
somatotropinoma may result from genetic and epigenetic alterations inducing the 
activation of oncogenes or inactivation of tumor suppressor genes [1]. Mutations in 
the alpha subunit of transmembrane G protein is observed in 40% of GH-secreting 
tumors [1]. This abnormality may cause constitutive activation of cyclin AMP 
(cAMP) and consequent hypersecretion of GH. Loss of expression of proapop-
totic molecules such as GADD45γ (growth arrest and DNA damage-inducible 45γ 
protein) and overexpression of oncoproteins, including PTTG (pituitary tumor-
transforming gene), are phenomena also observed in pituitary adenomas [17, 18].
Most cases of acromegaly occur sporadically; however, approximately 5% of 
cases may be related to inherited diseases such as multiple endocrine neoplasia 
type 1 (MEN1), Carney complex (CNC), and familial isolated pituitary adenoma 
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(FIPA) [17]. Germline mutations in aryl hydrocarbon receptor-interacting protein 
(AIP) gene seem to be the most frequent genetic alteration detected in sporadic 
and familial acromegaly patients [19]. The MEN1 and CNC are caused mainly by 
defects in genes MEN1 (menin) and PRKAR1A (regulatory subunit type 1 alpha), 
respectively [17].
3.2 Cross talk between acromegaly and thyroid cancer
The serum GH excess may promote proliferation and suppress apoptosis in many 
tissues [15]. Thus, it is suggested that acromegaly is responsible for the increased 
risk for development of many malignancies. PTC is the most common thyroid can-
cer observed in acromegaly [7, 9]. This type of pituitary tumor can also be associated 
with benign thyroid conditions such as diffuse and nodular goiters [9].
The mechanism of thyroid carcinogenesis in acromegaly is attributed to an auto-
crine/paracrine loop for GH/IGF-I in tumor tissue [8]. As the thyroid follicular cells 
also produce IGF-I and express genes encoding IGF-IR, the long-term exposure of 
thyrocyte to high GH/IGF-I levels may work synergically with this loop in promot-
ing goiter development and malignant transformation [20].
3.3  Molecular mechanisms and potential biomarkers of thyroid carcinogenesis 
in acromegaly
As shown in Figure 2, the molecular oncogenesis of PTC is mainly related to 
deregulation of mitogen-activated protein kinase (MAPK) signaling pathway 
and involves point mutations in BRAF and RAS genes and RET/PTC gene rear-
rangements [21, 22]. Analysis of these molecular markers can have diagnostic and 
prognostic implications in thyroid cancer.
Figure 1. 
Activation of JAK/STAT pathway mediated by GH (growth hormone). (a) JAK/STAT pathway components 
are inactive. (b) GH leads to dimerization of its receptor promoting phosphorylation of JAK and consequent 
activation of STAT proteins. (c) Once activated, STAT forms dimers that are translocated to the cell nucleus. 
(d) The STAT dimers in the nucleus are capable of binding to IGF-I promoter, initiating the transcription of 
this gene.
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3.3.1 BRAF mutation
BRAF (B-type RAF kinase) is a serine threonine kinase considered the most 
potent MAPK activator. This protein regulates important cellular processes such as 
proliferation, differentiation, and apoptosis [1].
In PTC, the main mechanism for activation of BRAF gene is a point mutation that 
promotes a substitution of nucleotide thymine by adenine at position 1799. This single 
nucleotide change promotes the replacement of valine by glutamate at protein residue 
600 (V600E). The BRAF V600E mutation is the most frequent genetic abnormality 
reported in thyroid carcinomas in the general population, particularly in PTC [21].
In acromegalic patients, the importance of BRAF V600E mutation on PTC 
carcinogenesis is still not well defined. In an Italian cohort of acromegalic patients, 
the BRAF V600E mutation was detected in 70% of cases with PTC, suggesting that 
this mutation is the main genetic driver of neoplastic transformation of thyroid cells 
in acromegaly [23]. On the other hand, other studies have demonstrated that the 
BRAF V600E mutation is infrequent in patients PTC with and without acromegaly 
[20, 24]. In these reports lower prevalence of this genetic alteration in acromegalic 
patients with PTC than non-acromegalic cases with PTC was verified. These results 
suggest that BRAF V600E mutation may not be a main mechanism of malignant 
transformation of thyroid cells in patients with acromegaly.
3.3.2 RAS mutations
The HRAS, KRAS, and NRAS are homologous gene members of the RAS 
(retrovirus-associated DNA sequences) family. These genes encode GTP-binding 
Figure 2. 
MAPK and PI3K pathways. (a) Growth factors bind to receptor tyrosine kinase and trigger the activation of 
(b) MAPK and/or (c) PI3K-AKT. (d) The signaling mediated to both pathways promotes the transcription of 
gene associated to different cellular processes such as proliferation and survival.
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proteins localized at the inner superficial of the cell membrane involved in signaling 
MAPK and PI3K-AKT pathways [1]. Together, RAS mutations are the second most 
frequent molecular alteration found in thyroid cancer, occurring in 10–20% of PTC 
cases and 40–50% of follicular carcinomas [22].
Point mutations are commonly restricted at codon 61 of the HRAS and NRAS 
genes and at codons 12 and 13 in the KRAS gene. RAS mutations in thyroid cancer 
have been associated to favorable prognosis such as tumor encapsulation and 
absence of metastases but also may represent a poor prognostic factor predisposing 
to cellular dedifferentiation and anaplastic transformation [22]. NRAS codon 61 
mutation has been referred as the most frequent genetic alteration in PTC patients 
with acromegaly. Aydin et al. pointed out that patients with NRAS codon 61 muta-
tion have aggressive histologic features such as vascular and capsular invasion [24]. 
However, another study revealed no case in a cohort of acromegalic patients with 
PTC-harbored RAS mutations [23]. These contradictory findings indicate that the 
importance of RAS mutational status in thyroid oncogenesis in acromegaly remains 
to be clarified.
3.3.3 RET/PTC rearrangements
The RET is a proto-oncogene that encodes a receptor-type tyrosine kinase with 
three domains: extracellular, transmembrane, and intracellular tyrosine kinase. 
The activation of this gene can contribute to the development of several neoplasms 
[25]. Rearrangements of RET that originated from fusion with unrelated genes 
(RET/PTC rearrangements) have been reported in thyroid follicular cells [26]. This 
genomic alteration can produce a chimeric oncoprotein with inappropriate tyrosine 
kinase activity able to continually stimulate the MAPK and PI3K-AKT pathways 
[26]. Among the fusion variants of RET, the rearrangements RET/PTC1 and RET/
PTC3 are the most frequent in thyroid cancer. Whereas in RET/PTC1 the RET gene 
is fused to CCDC6 (known as H4), in RET/PTC3 the rearrangement occurs with 
NCOA4 (known as ELE1 or RFG) [25]. RET/PTC rearrangement appears to be an 
important mechanism of thyroid carcinogenesis, but its frequency has oscillated in 
different reports. This genetic abnormality was not detected in PTC patients with 
acromegaly [24], although studies with this approach are rare in acromegaly.
3.3.4 Other molecular alterations
Besides the potential classic marker, other molecules have been evaluated in 
relation to their implication on PTC development in acromegaly, among them are 
IGF-I, IGF-IRβ, AIP, AHR, and galectin-3 (Gal-3) [20, 23–24, 27].
The analysis of immunohistochemical staining for IGF-IRβ revealed a high 
expression of this receptor in PTC samples [20]. Although differences in IGF-IRβ 
tumoral staining between PTC patients with and without acromegaly have not been 
observed, this marker had significantly less expression in adjacent normal tissue 
of patients with acromegaly. These data suggest that high GH levels may trigger 
autocrine and paracrine effects of IGF-I in thyroid follicular cells resulting in over-
expression of IGF-IRβ in tumor tissue of acromegalic patients. In line with these 
results, it was observed that PTC patients with acromegaly have higher expression 
of IGF-I than PTC cases without acromegaly [27]. Additionally, an intense expres-
sion was verified of Gal-3 in PTC with acromegaly, speculating a possible influence 
of this protein on thyroid carcinogenesis.
As previously mentioned, inactivation of AIP gene is frequently reported in 
pituitary tumors. However, this genetic abnormality seems not to be determinant 
to thyroid carcinogenesis in acromegalic patients [23]. Furthermore, there are no 
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differences in AIP protein expression between PTC in patients with and without 
acromegaly. Although immunohistochemical analysis for AIP receptor (AHR) has 
shown strong staining of PTC samples carrying BRAF V600E compared with wild 
type, differences were not found in AHR staining between PTC in acromegalic and 
non-acromegalic patients [23]. Thus, molecular alterations in AIP and AHR cannot 
be related to PTC carcinogenesis in acromegaly.
4. How to screen NTD in acromegalic patients
NTD seems to be significantly more frequent in patients with acromegaly. Even 
palpable thyroid nodules occur significantly more often in these patients [9, 13].
Periodic thyroid ultrasound (US) and careful evaluation of detected lesions are 
important parts in the follow-up of acromegalic patients. The sonographic charac-
teristics considered to be suspicious of TC, such as microcalcifications, irregular 
margins (infiltrative and microlobulated), taller than wide shape, and rim calci-
fications with small extrusive soft tissue component (evidence of extrathyroidal 
extension), are the same of the general population with NTD [5, 9].
Fine-needle aspiration (FNA) is the procedure of choice in the evaluation on 
NTD, and it should be performed when clinically indicated according to nodule’s 
size and US appearance. The FNA cytology result must be reported using the 
Bethesda System for Reporting Thyroid Cytopathology [9, 28].
In summary, as the risk of malignancy in thyroid nodules in these patients is 
about 8%, which is in the range considered for the general population, the manage-
ment of NTD should follow the current guidelines [9, 28].
5. How to treat TC in acromegalic patients
Although there is a risk of TC in acromegalic patients, its clinical behavior does 
not seem to be different [5]. Therefore, acromegalic patients with TC may be treated 
with total thyroidectomy or hemithyroidectomy according to its FNA result and size 
and the presence of clinically apparent metastatic lymph nodes [28].
Before surgery, we suggest that all acromegalic patients should do a preopera-
tive voice assessment (preoperative laryngeal exam—laryngoscopy) because they 
frequently have soft tissue thickening and edema of the tongue, pharynx, and upper 
airways [3]. Also, they must have a careful evaluation of comorbidities as hyperten-
sion, diabetes mellitus, and cardiovascular disease [3].
After surgery, these patients may or may not receive radioiodine depending, if it 
is a differentiated TC, on its risk of recurrence [28]. Studies about the relationship 
between medullary thyroid cancer (MTC) and acromegaly are lacking.
The frequency of US and laboratory tests during TC follow-up should follow the 
current guidelines.
6. Conclusion
NTC and TC are more frequent in acromegalic patients. On the other hand, 
the studies about potential mechanisms involved in this association between 
TC and acromegaly are still scarce, and besides they include small sample sizes. 
Furthermore, in these few reports, there is no marker clearly implicated on 
diagnosis or prognosis of PTC. Thus, further studies with this approach are 
needed.
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We suggest that acromegalic patients should be routinely screened by thyroid 
ultrasound and during their follow-up as necessary. Its management should follow 
the current guidelines. This is very important because it may allow early diagnosis 
and treatment of TC.
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